Fungal infections in recipients of hematopoietic stem cell transplants: Results of the SEIFEM B-2004 study - Sorveglianza Epidemiologica Infezioni Fungine nelle Emopatie Maligne

Clinical Infectious Diseases

Volumn 45, Issue 9, 2007, Pages 1161-1170

  Pagano, Livio ^a   Caira, M ^a   Nosari, A ^c   Van Lint, M T ^d   Candoni, A ^e   Offidani, M ^f   Aloisi, T ^g   Irrera, G ^h   Bonini, A ⁱ   Picardi, M ^j   Caramatti, C ^k   Invernizzi, R ^l   Mattei, D ^m   Melillo, L ⁿ   De Waure, C ^a   Reddiconto, G ^a   Fianchi, L ^a   Valentini, C G ^a   Girmenia, C ^b   Leone, G ^a   Aversa, F ^g   more..

^a CATHOLIC UNIVERSITY   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e UNIVERSITY OF UDINE   (Italy)

^f UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^g UNIVERSITY OF PERUGIA   (Italy)

^h BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

ⁱ S MARIA NUOVA HOSPITAL   (Italy)

^j UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^k UNIVERSITY OF PARMA   (Italy)

^l UNIVERSITY OF PAVIA   (Italy)

^m S CROCE E CARLE HOSPITAL   (Italy)

ⁿ Ospedale S Giovanni Rotondo   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; FLUCONAZOLE; ITRACONAZOLE; POLYENE; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANDIDA; CONTROLLED STUDY; FEMALE; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; INCIDENCE; ITALY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MOULD; MYCOSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TERTIARY HEALTH CARE; UNIVERSITY HOSPITAL; YEAST;

ADOLESCENT; ADULT; AGED; ASPERGILLOSIS; CANDIDIASIS; COHORT STUDIES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; ITALY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYCOSES; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 35348882622     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/522189     Document Type: Article

References (42)

1. Patterson TF, Kirkpatrick WR, White M , et al. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine 2000; 79:250-60.
2. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26:781-803.
3. Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM 2004 study. Haematologica 2006; 91:1068-75.
4. Muhlemann K, Wenger C, Zenhausern R, Tauber MG. Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies. Leukemia 2005; 19:545-50.
5. Nucci M, Spector N, Bueno AP, et al. Risk factors and attributable mortality associated with superinfections in neutropenic patients with cancer. Clin Infect Dis 1997; 24:575-9.
6. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000; 181:309-16.
7. Martino R, Subira M, Rovira M. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002; 116:475-82.
8. Jantunen E, Salonen J, Juvonen E, et al. Invasive fungal infections in autologous stem cell transplant recipients: a nation-wide study of 1188 transplanted patients. Eur J Haematol 2004; 73:174-8.
9. Grow WB, Moreb JS, Roque D, et al. Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant 2002; 29:15-9.
10. Cornet M, Fleury L, Maslo C, et al. Epidemiology of invasive aspergillosis in France: a six-year multicentric survey in the Greater Paris area. J Hosp Infect 2002; 51:288-96.
11. Morgan J, Wannemuehler KA, Marr KA, et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 2005; 43(Suppl 1):S49-58.
12. Zaoutis TE, Heydon K, Chu JH, Walsh TJ, Steinbach WJ. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics 2006; 117:e711-6.
13. Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001; 32:1319-24.
14. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34:909-17.
15. Fukuda T, Boeckh M, Carter RA, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003; 102:827-33.
16. Kojima R, Kami M, Nannya Y, et al. Incidence of invasive aspergillosis after allogeneic hematopoietic stem cell transplantation with a reduced-intensity regimen compared with transplantation with a conventional regimen. Biol Blood Marrow Transplant 2004; 10:645-52.
17. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175:1459-66.
18. Hagen EA, Stern H, Porter D, et al. High rate of invasive fungal infections following nonmyeloablative allogeneic transplantation. Clin Infect Dis 2003; 36:9-15.
19. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100:4358-66.
20. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32:358-66.
21. Girmenia C, Pagano L, Corvatta L, Mele L, del Favero A, Martino P. The epidemiology of fusariosis in patients with haematological diseases. Gimema Infection Programme. Br J Haematol 2000; 111:272-6.
22. Pagano L, Offidani M, Fianchi L, et al. Mucormycosis in hematologic patients. Haematologica 2004; 89:207-14.
23. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005; 191:1350-60.
24. Martino R, Subira M, Rovira M, et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002; 116:475-82.
25. Jantunen E, Ruutu P, Niskanen L, et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant 1997; 19:801-8.
26. Crippa F, Holmberg L, Carter RA, et al. Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2002; 8:281-9.
27. Kume H, Yamazaki T, Abe M, Tanuma H, Okudaira M, Okayasu I. Increase in aspergillosis and severe mycotic infection in patients with leukemia and MDS: comparison of the data from the Annual of the Pathological Autopsy Cases in Japan in 1989, 1993 and 1997. Path Int 2003; 53:744-50.
28. Kami M, Machida U, Okuzumi K, et al. Effect of fluconazole prophylaxis on fungal blood cultures: an autopsy-based study involving 720 patients with haematological malignancy. Br J Haematol 2002; 117:40-6.
29. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34:7-14.
30. Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 2000; 30:696-709.
31. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 2000; 30:662-78.
32. Hosmer DW, Lemeshow S. Applied logistic regression. New York:Wiley & Sons, 1989.
33. Upton A, Marr KA. Emergence of opportunistic mould infections in the hematopoietic stem cell transplant patient. Curr Infect Dis Rep 2006; 8:434-41.
34. Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41:1242-50.
35. Lionakis MS, Lewis RE, Torres HA, Albert ND, Raad II, Kontoyiannis DP. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli. Diagn Microbiol Infect Dis 2005; 52:15-20.
36. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007; 44:531-40.
37. Brion LP, Uko SE, Goldman DL. Risk of resistance associated with fluconazole prophylaxis: systematic review. J Infect 2007; 54:521-9.
38. Gualco L, Debbia EA, Bandettini R, et al. Antifungal resistance in Candida spp. isolated in Italy between 2002 and 2005 from children and adults. Int J Antimicrob Agents 2007; 29:179-84.
39. Mukherjee PK, Chandra J, Kuhn DM, Ghannoum MA. Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. Infect Immun 2003; 71:4333-40.
40. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-15.
41. Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39:1563-71.
42. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44:2-12.